Response to Comments: Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers

This article responds to public comments about the coverage of skin substitute grafts/cellular and tissue‑based products for diabetic foot ulcers and venous leg ulcers but does not itself list specific products or state coverage/exclusion decisions. It only notes that all comments from the named Medicare contractors were reviewed and addressed (some combined or cross‑referenced), so no new key requirements are specified in this document.